Salvianolic Acid C

SKU: orb1304489

Description

Salvianolic Acid C

Research Area

Metabolism Research

Key Properties

• CAS Number: 115841-09-3
• MW: 492.43
• Purity: 98.48%
• Formula: C₂₆H₂₀O₁₀
• SMILES: OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2oc(cc12)-c1ccc(O)c(O)c1
• Target: Cytochromes P450
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:5.5 mg/mL (11.17 mM);DMSO:55 mg/mL (111.69 mM)

Bioactivity

• Target IC50:
  CYP2J2:5.75 μM (Ki)|CYP2C8:4.82 μM (Ki)
• In Vivo:
  METHODS: To investigat the effects on liver injury, Salvianolic acid C (5-20 mg/kg) was intraperitoneally injected into C57BL/6J mice with CCl4-induced hepatic fibrosis once a day for Six days, followed by APAP (400 mg/kg) to induce liver injury. Results: Salvianolic acid C protects hepatocytes from APAP-induced injury by attenuating mitochondrial oxidative stress, inflammatory response, and cystatinase-mediated anti-apoptotic effects via Inhibition o the Keap1/Nrf2 hO-1 signaling axis.
• In Vitro:
  METHODS: Human periodontal stem cells hPDLSCs were pretreated with Salvianolic acid C (0-5 mM) for 1 h, then cultured with LPS (1 µg/mL) for 24 h. Cytokines were detected using ELISA kits. Results: Salvianolic acid C treatment significantly inhibite the expression of TNFα, IL-6 and IL-1β in a dose-dependent manner. METHODS: HEK293T cells stably expressing human-ACE2 were treated with Salvianolic acid C (0-100 µM), and viral entry was studied usin the SARS-CoV-2 hSCs pseudovirus (PsV) system. Results: Salvianolic acid C inhibited SARS-CoV-2 PsV entry on 293T/ACE2 cells with an IC50 of 3.85 µM

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Cytochrome P450, CYPs, Inhibitor, inhibit, Salvianolic Acid C

Compound Identifiers

PubChem CID

13991590